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Abstract: BACKGROUND: Facial hyperhidrosis is a disease that may lead patients to serious emotional disturbances.
Video-assisted thoracic sympathectomy provides excellent resolution of facial hyperhidrosis, but is associated
with certain complications. The most frequent and important complication is compensatory hyperhidrosis.
Especially in patients who have undergone resection of the second thoracic ganglion, the risk of severe compen-
satory hyperhidrosis is higher, which may cause dissatisfaction with the procedure. 
OBJECTIVE: The aim of this study was to evaluate the efficacy of the use of low doses of oxybutynin in treating facial
hyperhidrosis as well as the level of patient satisfaction with its use. 
METHODS: 25 patients with facial hyperhidrosis were treated with oxybutynin. The patients underwent 2 evalua-
tions: before and after treatment. These evaluations were used to assess the patients’ clinical improvement and
quality of life. 
RESULTS: We observed that more than 75% of the patients evolved with an improvement in facial hyperhidrosis,
and 52% of them presented a great improvement. 
CONCLUSION: Treatment of facial hyperhidrosis with oxybutynin is a good alternative to sympathectomy, since it
presents good results and improves quality of life, in addition to not exposing patients to the risk of experienc-
ing the side effects of sympathectomy. 
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Resumo: FUNDAMENTOS: Hiperidrose facial é uma doença que pode levar os pacientes a sérios distúrbios emo-
cionais. A simpatectomia torácica vídeo-assistida proporciona excelente resolução da hiperidrose facial, mas está
associada a algumas complicações, sendo a mais freqüente e mais importante a hiperidrose compensatória.
Especialmente em pacientes submetidos à ressecção do segundo gânglio torácico, o risco de hiperidrose com-
pensatória grave é maior, o que pode causar insatisfação com o procedimento. 
OBJETIVO: O objetivo deste estudo foi avaliar a eficácia e a satisfação dos pacientes com o uso da oxibutinina em
doses baixas para tratar a hiperidrose facial em uma série grande de pacientes. 
MÉTODOS: 25 pacientes com hiperidrose facial foram tratados com oxibutinina. Os pacientes foram submetidos a
duas avaliações: antes e depois do tratamento. Estas foram usadas para avaliar a melhoria clínica e a qualidade
de vida. 
RESULTADOS: Observou-se que mais de 75% dos pacientes evoluíram com melhora na hiperidrose facial, sendo que
52% deles apresentaram uma grande melhora. 
CONCLUSÃO: O tratamento da hiperidrose facial com oxibutinina é uma boa alternativa à simpatectomia, visto que
apresenta bons resultados e melhora a qualidade de vida, e os pacientes não correm o risco dos efeitos colaterais
da simpatectomia.
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INTRODUCTION
Facial hyperhidrosis (FH) is a disease that may
lead patients to serious emotional disturbances.1 Local
treatment and psychotherapy have low effectiveness.2
Video-assisted thoracic sympathectomy (VATS) provi-
des excellent resolution of facial hyperhidrosis, but is
associated with certain complications, especially with
compensatory hyperhidrosis, which is the most fre-
quent and important complication.3-6 This occurs, to a
mild degree, in most patients who have undergone
the treatment of palmar or axillary hyperhidrosis.
However, the risk is particularly higher in patients
treated for FH who have been submitted to the resec-
tion of the second thoracic ganglion, which may cause
dissatisfaction with the procedure. 7-9
Different anticholinergic drugs were used to
treat hyperhidrosis in the past, but their use did not
become routine due to side effects. 10
Oxybutynin is an anticholinergic drug that can
be safely used at high doses (over 15 mg/day) to treat
patients with urological disorders related to micturi-
tion.11 An effect observed in such patients is diminis-
hed sudoresis. Its use for treating hyperhidrosis has
only been described in three case reports on patients
with hyperhidrosis and one series of 14 patients with
compensatory hyperhidrosis. 12-15 Daily practice has
shown us that oxybutynin at low doses (up to 10
mg/day) seems to generate fewer side effects, while it
is still effective to reduce sudoresis in patients with
facial hyperhidrosis.
Considering that the main treatment for facial
hyperhidrosis is botulinum toxin or surgical procedu-
res (video-assisted thoracic sympathectomy), which
are often accompanied by unpleasant side effects, oxy-
butynin provides a possible alternative for its treat-
ment.
The aim of the present study was to evaluate
the effectiveness of the use of oxybutynin at low doses
for treating facial hyperhidrosis in a large series of
patients as well as to evaluate patient satisfaction with
the treatment.
MATERIALS & METHODS
This was a non-randomized and uncontrolled
study carried out in accordance with the ethical stan-
dards of the university’s Committee of Ethics for
Analysis of Research Projects on Human
Experimentation. From January 2007 to June 2009, 25
consecutive patients with facial hyperhidrosis were
treated with oxybutynin. Of these, six patients were
lost to follow-up. Thus, data were collected from 19
patients who underwent clinical treatment. Patients
with glaucoma were not treated.
All of the patients underwent similar treatment
following the same protocol. During the first week,
they received 2.5 mg of oxybutynin once a day in the
evening. From the eighth to the 42nd day, they received
2.5 mg twice a day, and from the 43rd day to the end of
the 12th week, they received 5 mg twice a day.
The patients were between 20 and 62 years old,
with a mean of 41.8 ± 14.0 years and median of 43.0
years. The group was composed of 9 women and 10
men. The patients’ body mass index (BMI) ranged
from 22.6 to 36.7, with a mean of 28.0 ± 3.7 and
median of 27.0. 
In addition to facial hyperhidrosis, all of them
presented hyperhidrosis in other sites of the body:
thoracic and abdominal hyperhidrosis was observed
in 10 patients (40%), palmar in 9 (36%), axillary in 7
(28%), and plantar in 5 (20%). 
All of the patients underwent 3 evaluations for
the purpose of this study. The first evaluation was car-
ried out before the medication treatment, the second
after 6 weeks of treatment and the last after 12 weeks
of treatment. These were used to assess (1) the
patients’ clinical improvement of facial hyperhidrosis
and the improvement of hyperhidrosis in other sites
of the body, as reported by the patients by means of a
clinical questionnaire; and (2) their quality of life
(QOL), using a clinical protocol for QOL which was
administered at each visit. 16,17
The patients completed the clinical improve-
ment questionnaire according to their subjective per-
ception of improvement of sudoresis. They evaluated
it on a scale ranging from 0 to 10, in a way that 0
represented no improvement and 10 represented
absence of hyperhidrosis, based on their own estima-
tes without any intervention or advice from the inter-
viewer. The improvement was recorded as null when
the score was 0; slight, when it was 1 to 4; moderate,
when it was 5 to 7; or great, when it was 8 to 10. 
Quality of life before treatment was classified
into five different satisfaction levels, calculated as the
summed total score from the protocol (ranging from
20 to 100). When the total was greater than 84, the
QOL was considered very poor; from 68 to 83, poor;
from 52 to 67, good; from 36 to 51, very good; and
from 20 to 35, excellent. 
Improvement of QOL after treatment was also
classified into 5 different evolution levels. When the
total was greater than 84, the QOL was considered
much worse; from 68 to 83, slightly worse; from 52 to
67, the same; from 36 to 51, slightly better; and from
20 to 35, much better.
The following parameters were studied: evolu-
tion of facial hyperhidrosis; evolution of hyperhidrosis
in other sites of the body; evaluation of QOL before
treatment; evaluation of improvement in QOL after
treatment; analysis of the patients’ evolution accor-
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ding to QOL levels before treatment; analysis of
improvement in QOL according to gender, age, and
BMI; and finally, any complications and side effects.
Statistical analysis
For categorical variables, the 
¯2
or the Student t
test was used. These statistical tests were used for
comparing gender, age, and BMI with satisfaction
(QOL). The associations between improvement of
QOL according to the levels observed before treat-
ment were investigated using the McNemar test. The
significance level considered for all tests was P = 0.05. 
RESULTS
As pointed out previously, 24% of the patients
were lost during follow-up. The results of the treat-
ment related to facial hyperhidrosis are presented in
table 1.
More than 75% of the patients evolved with an
improvement in facial hyperhidrosis, and 52% of them
presented a great improvement.
The results of the treatment related to other
sites of hyperhidrosis reported by the patients are pre-
sented in table 2.
More than 80% of the patients showed improve-
ments in all of the sites presenting hyperhidrosis.
There were no cases of worsening in other sites of
hyperhidrosis.
The distribution of QOL before and after treat-
ment is presented in table 3.
Before treatment, all of the patients presented
poor or very poor QOL. The median was 0.81 (±
0.10).
After treatment, most of the patients presented
improvements (73.6%). The median was 0.40 (±
0.12).
The analysis on the evolution of QOL among
the patients, according to the levels observed before
treatment, is presented in table 4.
The patients with poor QOL before treatment
presented the same results as those with very poor
QOL before treatment.
The analysis of the evolution of QOL according
to the patients’ gender, age, and BMI is presented in
table 5.
There were no statistical differences in
patients’ evolution in relation to gender, age, or BMI.
Certain side effects were observed during the
treatment. Headache was presented by one patient
(5.2%) while using 5 mg of oxybutynin per day and by
one patient (5.2%) while using 10 mg/day. In both
cases, the headache disappeared with the use of com-
mon analgesics. Urine retention was reported by one
patient (5.2%) while using 10 mg/day. No bladder
drainage or suspension of oxybutynin was necessary
in this patient.
Dry mouth was the side effect most frequently
reported and was reported by the majority of the
patients (70.5%). 
Most of the patients presented some degree of
dry mouth during the treatment. The frequency and
intensity of this side effect increased with higher
doses.
DISCUSSION
There has been an increasing demand for treat-
ment of hyperhidrosis worldwide because of the
excellent results obtained with sympathectomy in
treating patients with this condition, the widespread
publicity about this disease in the current media, and
the great incidence of this condition. 18
Differently from palmar hyperhidrosis, in
which symptoms most frequently start in childhood,
patients with facial hyperhidrosis start experiencing
its symptoms in adulthood. 19, 20 For this reason, most
patients that seek treatment are adults in their forties.
There is no female predominance as seen in other
sites of hyperhidrosis, probably because this type of
excessive sweating has greater repercussions in men’s
daily lives than in women’s. 21
Patients using oxybutynin to treat urinary disor-
ders take larger doses (15 mg/day) and may present
more severe side effects (dry mouth, headache, and
urine retention).22 However, we did not observe this
with the low and progressive doses used in the pre-
sent study. The clinical treatment used by our group
is well standardized. We start the treatment with very
low doses of oxybutynin (2.5 mg/day) and progressi-
vely increase the dose up to 10 mg/day. We use this
protocol because patients with urinary disorders were
instructed to start taking 5 mg every 12 hours and pre-
sented greater severity of dry mouth right at the
beginning of the treatment. This discomfort led some
patients to abandon the treatment. Through empirical
practice, we found out that the incidence of side
effects was lower when starting with very low doses
(2.5 mg/day) and increasing them progressively (up to
10 mg/day). Moreover, when such effects did occur,
patients were able to adapt to them better. 
Improvement N0. (%)
Facial hyperhidrosis Worse 0 (0.0)
null 1 (5.2)
slight 3 (15.8)
moderate 5 (26.4)
great 10 (52.6)
TABLE 1: Evolution of facial hyperhidrosis with the
use of oxybutynin
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Dry mouth was the most frequently observed
side effect. Using 5 mg of oxybutynin per day, 68.3
% of the patients either did not present dry mouth
or presented it mildly, which encouraged the
patients to proceed with the treatment. Using 10 mg
per day, this symptom increased but was well tolera-
ted. None of the patients abandoned the treatment
due to this side effect. Moreover, less frequent side
effects such as slight headache and urine retention
were not a reason for the patients to discontinue
the treatment. 
The patients who sought medical assistance
presented great dissatisfaction regarding facial hype-
rhidrosis. The degree of degradation of their low QOL
was measured in our study by means of a specific QOL
questionnaire on hyperhidrosis that has been valida-
ted and used in several published studies. 23
The degree to which hyperhidrosis worsens a
patient’s QOL depends not only on the severity of the
condition but also on the patient’s adaptation to it. 24
Some individuals with less severe hyperhidrosis pre-
sent very poor QOL, whereas patients with very seve-
re hyperhidrosis may report that their QOL is not so
poor, because they have adapted better to their condi-
tion. All of the patients treated in this sample presen-
ted poor or very poor QOL. 
Basically all patients in good clinical condition,
except those who present glaucoma, can be treated
with oxybutynin. This includes obese patients (the
patients in this study have a body mass index of 28).
With surgery, such patients might present greater risk
of developing compensatory hyperhidrosis, in addi-
tion to the surgical risk. 
We did not use any objective measurement of
sudoresis because this kind of method only produces
data at a specific point in time. There are no methods
that can measure hyperhidrosis over an entire day. For
this reason, we asked the patients to grade their
improvement on a scale from 0 to 10 for each of the
sites presenting hyperhidrosis reported.
The results obtained for treating facial hyperhi-
drosis were satisfactory. However, a 24% loss of fol-
low-up can be a study limitation, because a large num-
ber of losses like this may have caused a selection bias.
Facial sudoresis decreased in more than 75% of the
cases, and in 73.2% of the cases with regard to QOL.
When surgery is performed, the results are even bet-
ter, given that more than 95% of the patients become
free from facial hyperhidrosis. On the other hand,
sympathectomy may give rise to compensatory hype-
rhidrosis, i.e. an irreversible increase in sudoresis in
other sites of the body. 25 In the present sample, we
found that almost all of the patients presented hype-
rhidrosis in other sites, predominantly in the thoracic,
abdominal, palmar and plantar regions. With drug
treatment, we found that there was a great improve-
ment (more than 80%) in all of the other sites presen-
ting hyperhidrosis.
Improvement 
Hyperhidrosis site no. (%)
null slight moderate great total
Thoracic + abdominal 0 1 (10.0) 8 (80.0) 1 (10.0) 10
Palmar 0 1 (11.1) 3 (33.3) 5 (55.6) 9
Axillary 0 0 5 (71.4) 2 (28.6) 7
Plantar 0 1 (20.0) 1 (20.0) 3 (60.0) 5
TABLE 2: Evolution of hyperhidrosis with the use of oxybutynin
QOL before QOL after 
treatment treatment
0.20 - 0.35 (excellent) 0 7 (36.8%)
0.36 - 0.51 (very good) 0 7 (36.8%)
0.52 - 0.67 (good) 0 5 (26.4%)
0.68 - 0.83 (poor) 10 (52.6%) 0
0.84 - 1.00 (very poor) 9 (47.4%) 0
TABLE 3: Quality of life (QOL) before and after oxy-
butynin treatment
After treatment
Much better and a The same P value
little better
6 (60.0%) 4 (40.0%) 0.3877
8 (88.9%) 1 (11.1%)
TABLE 4: Evolution of quality of life according to the
levels before treatment
P value obtained using the McNemar test=
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The prognostic factors currently associated with
worsening of QOL following thoracic sympathectomy
to treat hyperhidrosis are surgical failure and severe
compensatory hyperhidrosis. 26, 27 On the other hand,
with clinical treatment, we did not observe any worse-
ning of QOL. In the worst cases, QOL remained
unchanged. When patients wish, medication may be
discontinued and surgical treatment may be chosen,
provided that these patients are properly assisted and
informed about the main side effect resulting from the
surgical procedure, i.e. compensatory hyperhidrosis.
Based on analyses of the prognostic factors for
improvement of QOL through treatment with oxy-
butynin, we found that there was no difference in evo-
lution of quality of life compared with the levels of
QOL before treatment. Age, gender, and BMI were
also unrelated to the patients’ evolution. 
We believe that in addition to the effectiveness
presented, this therapeutic alternative is an excellent
choice for the initial treatment of facial hyperhidrosis.
Patients who choose this treatment have nothing to
lose, and the least to be expected is that it will help
prepare them to face sympathectomy in the future.
CONCLUSIONS
Treatment of facial hyperhidrosis with oxybuty-
nin represents a good alternative to sympathectomy,
since it produces good results and improves QOL.
Moreover, patients do not face the risk of experiencing
the side effects of sympathectomy. 
An Bras Dermatol. 2011;86(3):451-6.
Variable Category QOL much better + QOL the same P value
slightly better Freq. Freq. (%) or
(%) or measurement measurement
Gender Female 10 (72.1) 1 (27.9) >0.111
Male 4 (75.8) 4 (24.2)
Age (years) N 14 5 0.6341 *
Range 20.5 – 62.6 22.5 – 59.8
Median 42.5 43.0
Mean 42.6 39.1
Standard deviation 13.5 15.0
BMI N 14 5 0.3470 *
Range 22.6 – 36.7 23.7 – 30.5
Median 28.4 26.8
Mean 28.9 27.0
Standard deviation 4.1 2.4
TABLE 5: Evolution of quality of life (QOL) according to patients’ gender, age and BMI
P value obtained using the chi-square test
* P value obtained using the Student t test
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